Clinical Trials Testing Viread in MSM for HIV Prevention to Begin in Atlanta, San Francisco
December 2, 2004
Clinical trials of the antiretroviral drug Viread among HIV-negative men who have sex with men will begin this month in San Francisco and Atlanta to determine whether the drug can reduce the risk of HIV infection, the San Francisco Chronicle reports (Russell, San Francisco Chronicle, 12/1). NIH, CDC and the Bill & Melinda Gates Foundation are funding three separate human studies of Viread, which is known generically as tenofovir and manufactured by Gilead Sciences. The drug is FDA-approved for use as a treatment for HIV infection and has been shown to boost immune response and lower viral levels in the bloodstreams of patients who are resistant to other antiretrovirals. CDC has granted $3.5 million to fund the trials in San Francisco and Atlanta, while the Gates Foundation awarded a $6.5 million grant to Family Health International to conduct a randomized, placebo-controlled clinical trial including 2,000 HIV-negative volunteers in Cambodia, Ghana, Cameroon, Nigeria and Malawi. NIH also awarded a $2.1 million grant to University of California-San Francisco researchers to test Viread in 960 HIV-negative Cambodian women, most of whom are commercial sex workers (Kaiser Daily HIV/AIDS Report, 2/6). However, Cambodian Prime Minister Hun Sen in August ordered a stop to the planned human clinical trial in the country because of the possible effects of the drug on trial participants (Kaiser Daily HIV/AIDS Report, 8/12).
Reprinted with permission from kaisernetwork.org. You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at www.kaisernetwork.org/dailyreports/hiv. The Kaiser Daily HIV/AIDS Report is published for kaisernetwork.org, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Number of New U.S. HIV Infections Holds Steady; Proportion of Cases Among Blacks, MSM Increases, CDC Data Say
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.